NCT01826266View on ClinicalTrials.gov

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Anticoagulant ReversalReversal of Edoxaban Induced Anticoagulation
Interventions
DRUG

PER977, Placebo

Trial Locations (1)

27705

Duke Clinical Research, Unit 200, Durham

All Listed Sponsors
lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT01826266 - Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban | Biotech Hunter | Biotech Hunter